医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FortuneRock (China) Co., Ltd. Announces Initial Public Offering (IPO) on National Equities Exchange and Quotations (NEEQ:833178) in China

2015年08月10日 PM08:54
このエントリーをはてなブックマークに追加


 

BEIJING

FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company, announced that it has received approval for its initial public offering and listing on the National Equities Exchange and Quotations (NEEQ) or “Xin San Ban” by Chinese regulators on July 30, 2015. The company shares will trade under the new ticker number “NEEQ:833178″.

The company preliminary prospectus and information has been filed with the securities commissions regulatory authorities in China. The preliminary prospectus remains subject to completion or amendment.

Prof. Zailin YU, Chairman of FortuneRock (China) Co., Ltd. said, “We are happy to announce the successful IPO of our business in China on the NEEQ. This continues our efforts to further expand the company and our extensive novel product pipeline.”

About FortuneRock (China) Co., Ltd.

FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with high clinical value for the treatment of life-threatening and debilitating diseases. Currently, the company has one drug with clinical Phase I completed, one in later stage clinical Phase II, another waiting for approval to enter into clinical trials, and several novel drugs in pre-clinical studies, all for different indications.

FortuneRock (China) Co., Ltd. has unique technology platforms with 26 patents filed or granted in USA, China or PCT and all have been published. The Long Acting Recombinant Protein Drug Platform can be used for developing many therapeutic protein drugs for injection with longer half-life or long acting functions on the restructuring of the well known recombinant protein drugs. Along with a High Efficacy Yeast Expression System Platform, FortuneRock can produce kilogram mass quantities of high quality recombinant protein products. FortuneRock has extensive experience in product development and conducting pre-clinical and clinical trials in China for itself and its partners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150810005333/en/

CONTACT

FortuneRock (China) Co., Ltd.
Ms. Lili ZHOU, +86-10-6276-0812
Secretary
of the Board of Directors
lili@fortunerock.com;
lilizhou_312@163.com
www.fortunerock.com;
www.tsbsino.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent